Imugene Reports Encouraging Efficacy from Phase Ib Azer-cel Trial in DLBCL

Imugene has shared promising interim data from its ongoing Phase Ib trial of azer-cel (azercabtagene zapreleucel), an off-the-shelf CAR T-cell therapy, in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. Designed to overcome the limitations of autologous CAR T therapies, azer-cel offers broader accessibility and faster treatment timelines.

The multi-centre, open-label trial in the US and Australia initially focused on CAR T-relapsed DLBCL patients and has expanded to include CAR T-naïve patients with various non-Hodgkin’s lymphomas, including chronic lymphocytic leukemia, primary CNS lymphoma, and Waldenstrom macroglobulinemia.

As of September 2025, 13 of 16 participants achieved an overall response rate (ORR) of 81%. With one additional patient showing a partial response, the ORR increased to 82% (14 of 17 participants). Responses, particularly in patients treated with IL-2 alongside azer-cel, are becoming increasingly durable. Imugene is actively enrolling participants across ten US sites, with six Australian sites underway.

01-12-2025